Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evolving strategies for renoprotection: diabetic nephropathy.

H H Parving1, P Hovind, K Rossing

  • 1Steno Diabetes Center, Copenhagen, Denmark.

Current Opinion in Nephrology and Hypertension
|July 18, 2001
PubMed
Summary

Diabetic nephropathy affects 25-40% of patients with diabetes. Key treatments include improved blood sugar control and blood pressure management with angiotensin-converting enzyme inhibitors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sarcopenia and self-reported markers of physical frailty in patients with osteoporosis.

Archives of osteoporosis·2024
Same author

Estimated GFR: Are There Limits to Its Utility?: Monitoring Kidney Function in Type 2 Diabetic Patients with Incipient and Overt Diabetic Nephropathy. Diabetes Care 29: 1024-1030, 2006.

Journal of the American Society of Nephrology : JASN·2023
Same author

Baseline bone turnover marker levels can predict change in bone mineral density during antiresorptive treatment in osteoporotic patients: the Copenhagen bone turnover marker study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2022
Same author

Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-study.

Diabetic medicine : a journal of the British Diabetic Association·2020
Same author

Prevalence of muscle dysfunction concomitant with osteoporosis in a home-dwelling Danish population aged 65-93 years - The Copenhagen Sarcopenia Study.

Experimental gerontology·2020
Same author

Association between severe diabetic retinopathy and lectin pathway proteins - an 18-year follow-up study with newly diagnosed type 1 diabetes patients.

Immunobiology·2020

Area of Science:

  • Nephrology
  • Endocrinology
  • Diabetology

Background:

  • Diabetic nephropathy affects 25-40% of patients with diabetes and is a leading cause of end-stage renal failure.
  • Historically, limited treatment options existed, with death often occurring 5-7 years after proteinuria onset.
  • Treatment advancements emerged in the 1980s and 1990s, focusing on antihypertensive therapy, glycemic control, and ACE inhibition.

Purpose of the Study:

  • To review current treatment strategies for diabetic nephropathy.
  • To highlight the efficacy of primary and secondary prevention methods.
  • To discuss the impact of antihypertensive treatment on disease progression and survival.

Main Methods:

  • Review of megatrials and meta-analyses on diabetic nephropathy treatments.

Related Experiment Videos

  • Analysis of studies on primary and secondary prevention strategies.
  • Evaluation of antihypertensive therapy in patients with overt nephropathy.

    • Main Results:

    • Improved glycemic control and blood pressure lowering (especially with ACE inhibitors) are key for primary prevention.
    • ACE inhibitors are effective for secondary prevention in high-risk patients (e.g., those with microalbuminuria).
    • Antihypertensive treatment reduces albuminuria, slows GFR decline, delays end-stage renal failure, and improves survival.

    Conclusions:

    • Effective management strategies for diabetic nephropathy include glycemic control, blood pressure management, and ACE inhibitors.
    • These interventions significantly reduce the risk of progression and improve outcomes.
    • Ongoing research continues to explore novel treatment modalities.